SG175816A1

SG175816A1 - Phosphotetrahydropyran compounds for the treatment of wounds and fibrotic disorders

Phosphotetrahydropyran compounds for the treatment of wounds and fibrotic disorders Download PDF

Info

Publication number: SG175816A1
Authority: SG; Singapore
Prior art keywords: formula; group; compound; aryl; fibrosis
Prior art date: 2009-04-28

Application number

SG2011079274A

Other languages

English (en)

Inventor

Alan D Robertson

Diego Silva

Ian Alexander Mcdonald

Original Assignee

Pharmaxis Pty Ltd

Priority date

2009-04-28

Filing date

2010-04-28

Publication date

2011-12-29

2010-04-28 Application filed by Pharmaxis Pty Ltd filed Critical Pharmaxis Pty Ltd

2011-12-29 Publication of SG175816A1 publication Critical patent/SG175816A1/en

Links

208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 49
238000011282 treatment Methods 0.000 title claims abstract description 29
230000003176 fibrotic effect Effects 0.000 title claims abstract description 28
208000027418 Wounds and injury Diseases 0.000 title claims description 34
206010052428 Wound Diseases 0.000 title claims description 28
HOGAGKVTOGTBKP-UHFFFAOYSA-N O=P(=O)C1CCCCO1 Chemical class O=P(=O)C1CCCCO1 HOGAGKVTOGTBKP-UHFFFAOYSA-N 0.000 title abstract description 55
238000000034 method Methods 0.000 claims abstract description 83
238000001356 surgical procedure Methods 0.000 claims abstract description 45
208000035475 disorder Diseases 0.000 claims abstract description 30
208000010412 Glaucoma Diseases 0.000 claims abstract description 20
208000005069 pulmonary fibrosis Diseases 0.000 claims abstract description 15
230000029663 wound healing Effects 0.000 claims abstract description 10
150000001875 compounds Chemical class 0.000 claims description 96
-1 phosphotetrahydropyran compound Chemical class 0.000 claims description 74
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 40
102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 36
108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 36
102000008186 Collagen Human genes 0.000 claims description 35
108010035532 Collagen Proteins 0.000 claims description 35
229920001436 collagen Polymers 0.000 claims description 35
125000000217 alkyl group Chemical group 0.000 claims description 33
210000001519 tissue Anatomy 0.000 claims description 25
229940002612 prodrug Drugs 0.000 claims description 23
239000000651 prodrug Substances 0.000 claims description 23
150000003839 salts Chemical class 0.000 claims description 23
239000000203 mixture Substances 0.000 claims description 21
125000003118 aryl group Chemical group 0.000 claims description 20
201000010099 disease Diseases 0.000 claims description 18
210000004072 lung Anatomy 0.000 claims description 18
201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 15
230000008021 deposition Effects 0.000 claims description 15
208000036971 interstitial lung disease 2 Diseases 0.000 claims description 15
102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 14
108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 14
210000002744 extracellular matrix Anatomy 0.000 claims description 14
239000003937 drug carrier Substances 0.000 claims description 13
102000016359 Fibronectins Human genes 0.000 claims description 12
108010067306 Fibronectins Proteins 0.000 claims description 12
125000002252 acyl group Chemical group 0.000 claims description 12
229960003957 dexamethasone Drugs 0.000 claims description 12
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 12
239000003814 drug Substances 0.000 claims description 12
229910052739 hydrogen Inorganic materials 0.000 claims description 12
230000008569 process Effects 0.000 claims description 12
125000001424 substituent group Chemical group 0.000 claims description 12
230000004054 inflammatory process Effects 0.000 claims description 11
125000001072 heteroaryl group Chemical group 0.000 claims description 10
206010061218 Inflammation Diseases 0.000 claims description 9
YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 claims description 8
238000004519 manufacturing process Methods 0.000 claims description 8
206010039710 Scleroderma Diseases 0.000 claims description 7
230000008439 repair process Effects 0.000 claims description 7
125000003107 substituted aryl group Chemical group 0.000 claims description 7
238000002316 cosmetic surgery Methods 0.000 claims description 5
125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 5
108010008165 Etanercept Proteins 0.000 claims description 4
PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims description 4
239000005517 L01XE01 - Imatinib Substances 0.000 claims description 4
239000005411 L01XE02 - Gefitinib Substances 0.000 claims description 4
FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 claims description 4
BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 claims description 4
208000001647 Renal Insufficiency Diseases 0.000 claims description 4
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 4
229960004308 acetylcysteine Drugs 0.000 claims description 4
HAMNKKUPIHEESI-UHFFFAOYSA-N aminoguanidine Chemical compound NNC(N)=N HAMNKKUPIHEESI-UHFFFAOYSA-N 0.000 claims description 4
XFILPEOLDIKJHX-QYZOEREBSA-N batimastat Chemical compound C([C@@H](C(=O)NC)NC(=O)[C@H](CC(C)C)[C@H](CSC=1SC=CC=1)C(=O)NO)C1=CC=CC=C1 XFILPEOLDIKJHX-QYZOEREBSA-N 0.000 claims description 4
229950001858 batimastat Drugs 0.000 claims description 4
229960003065 bosentan Drugs 0.000 claims description 4
VLCYCQAOQCDTCN-UHFFFAOYSA-N eflornithine Chemical compound NCCCC(N)(C(F)F)C(O)=O VLCYCQAOQCDTCN-UHFFFAOYSA-N 0.000 claims description 4
229960000403 etanercept Drugs 0.000 claims description 4
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
229960002584 gefitinib Drugs 0.000 claims description 4
XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims description 4
229960002411 imatinib Drugs 0.000 claims description 4
KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims description 4
208000011379 keloid formation Diseases 0.000 claims description 4
201000006370 kidney failure Diseases 0.000 claims description 4
229960004584 methylprednisolone Drugs 0.000 claims description 4
229960001476 pentoxifylline Drugs 0.000 claims description 4
229960003073 pirfenidone Drugs 0.000 claims description 4
ISWRGOKTTBVCFA-UHFFFAOYSA-N pirfenidone Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC=C1 ISWRGOKTTBVCFA-UHFFFAOYSA-N 0.000 claims description 4
229960005205 prednisolone Drugs 0.000 claims description 4
OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims description 4
229960004586 rosiglitazone Drugs 0.000 claims description 4
229960003048 vinblastine Drugs 0.000 claims description 4
JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims description 4
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 3
108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 3
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 3
201000002793 renal fibrosis Diseases 0.000 claims description 3
159000000000 sodium salts Chemical class 0.000 claims description 3
208000021945 Tendon injury Diseases 0.000 claims description 2
208000019425 cirrhosis of liver Diseases 0.000 claims description 2
239000002537 cosmetic Substances 0.000 claims description 2
UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 claims 3
241000766026 Coregonus nasus Species 0.000 claims 1
101100448208 Human herpesvirus 6B (strain Z29) U69 gene Proteins 0.000 claims 1
GJPICJJJRGTNOD-UHFFFAOYSA-N bosentan Chemical compound COC1=CC=CC=C1OC(C(=NC(=N1)C=2N=CC=CN=2)OCCO)=C1NS(=O)(=O)C1=CC=C(C(C)(C)C)C=C1 GJPICJJJRGTNOD-UHFFFAOYSA-N 0.000 claims 1
230000009787 cardiac fibrosis Effects 0.000 claims 1
210000002615 epidermis Anatomy 0.000 claims 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
210000001835 viscera Anatomy 0.000 claims 1
230000037390 scarring Effects 0.000 abstract description 27
206010016654 Fibrosis Diseases 0.000 abstract description 16
230000004761 fibrosis Effects 0.000 abstract description 16
230000035876 healing Effects 0.000 abstract description 8
210000003734 kidney Anatomy 0.000 abstract description 7
230000001434 glomerular Effects 0.000 abstract description 6
210000002435 tendon Anatomy 0.000 abstract description 6
230000036573 scar formation Effects 0.000 abstract description 3
230000002784 sclerotic effect Effects 0.000 abstract description 2
238000012360 testing method Methods 0.000 description 62
210000004027 cell Anatomy 0.000 description 54
241000699670 Mus sp. Species 0.000 description 27
241001465754 Metazoa Species 0.000 description 22
230000000694 effects Effects 0.000 description 19
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 18
102000015225 Connective Tissue Growth Factor Human genes 0.000 description 17
108010039419 Connective Tissue Growth Factor Proteins 0.000 description 17
210000002950 fibroblast Anatomy 0.000 description 17
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 16
239000011780 sodium chloride Substances 0.000 description 16
238000001914 filtration Methods 0.000 description 15
108020003175 receptors Proteins 0.000 description 15
102000005962 receptors Human genes 0.000 description 15
108010006654 Bleomycin Proteins 0.000 description 14
229960001561 bleomycin Drugs 0.000 description 14
OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 14
230000002829 reductive effect Effects 0.000 description 14
231100000241 scar Toxicity 0.000 description 14
210000001508 eye Anatomy 0.000 description 13
230000005764 inhibitory process Effects 0.000 description 12
238000002347 injection Methods 0.000 description 12
239000007924 injection Substances 0.000 description 12
230000004044 response Effects 0.000 description 12
125000000304 alkynyl group Chemical group 0.000 description 11
239000005557 antagonist Substances 0.000 description 11
230000004410 intraocular pressure Effects 0.000 description 11
239000000243 solution Substances 0.000 description 11
208000029523 Interstitial Lung disease Diseases 0.000 description 10
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 10
239000002953 phosphate buffered saline Substances 0.000 description 10
125000003342 alkenyl group Chemical group 0.000 description 9
230000006378 damage Effects 0.000 description 9
229940079593 drug Drugs 0.000 description 9
238000001990 intravenous administration Methods 0.000 description 9
229960004857 mitomycin Drugs 0.000 description 9
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
210000001742 aqueous humor Anatomy 0.000 description 8
230000015572 biosynthetic process Effects 0.000 description 8
210000004369 blood Anatomy 0.000 description 8
239000008280 blood Substances 0.000 description 8
238000002474 experimental method Methods 0.000 description 8
239000008103 glucose Substances 0.000 description 8
208000014674 injury Diseases 0.000 description 8
238000009825 accumulation Methods 0.000 description 7
230000004913 activation Effects 0.000 description 7
208000002352 blister Diseases 0.000 description 7
239000002158 endotoxin Substances 0.000 description 7
239000000835 fiber Substances 0.000 description 7
239000012530 fluid Substances 0.000 description 7
229920006008 lipopolysaccharide Polymers 0.000 description 7
235000018102 proteins Nutrition 0.000 description 7
102000004169 proteins and genes Human genes 0.000 description 7
108090000623 proteins and genes Proteins 0.000 description 7
NBSCHQHZLSJFNQ-QTVWNMPRSA-N D-Mannose-6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@@H]1O NBSCHQHZLSJFNQ-QTVWNMPRSA-N 0.000 description 6
PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 6
241000699666 Mus <mouse, genus> Species 0.000 description 6
102000003896 Myeloperoxidases Human genes 0.000 description 6
108090000235 Myeloperoxidases Proteins 0.000 description 6
125000000753 cycloalkyl group Chemical group 0.000 description 6
PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 6
239000000499 gel Substances 0.000 description 6
229960002591 hydroxyproline Drugs 0.000 description 6
230000002757 inflammatory effect Effects 0.000 description 6
238000013508 migration Methods 0.000 description 6
210000000651 myofibroblast Anatomy 0.000 description 6
230000000750 progressive effect Effects 0.000 description 6
230000011664 signaling Effects 0.000 description 6
230000009885 systemic effect Effects 0.000 description 6
FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
108091003079 Bovine Serum Albumin Proteins 0.000 description 5
241000283973 Oryctolagus cuniculus Species 0.000 description 5
241000700159 Rattus Species 0.000 description 5
125000004432 carbon atom Chemical group C* 0.000 description 5
230000001684 chronic effect Effects 0.000 description 5
230000003247 decreasing effect Effects 0.000 description 5
210000004969 inflammatory cell Anatomy 0.000 description 5
230000004941 influx Effects 0.000 description 5
239000002609 medium Substances 0.000 description 5
230000005012 migration Effects 0.000 description 5
229940071127 thioglycolate Drugs 0.000 description 5
CWERGRDVMFNCDR-UHFFFAOYSA-M thioglycolate(1-) Chemical compound [O-]C(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-M 0.000 description 5
210000001585 trabecular meshwork Anatomy 0.000 description 5
238000011740 C57BL/6 mouse Methods 0.000 description 4
208000032544 Cicatrix Diseases 0.000 description 4
WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
208000002260 Keloid Diseases 0.000 description 4
101800001155 Latency-associated peptide Proteins 0.000 description 4
102400000401 Latency-associated peptide Human genes 0.000 description 4
208000022873 Ocular disease Diseases 0.000 description 4
206010030348 Open-Angle Glaucoma Diseases 0.000 description 4
238000003556 assay Methods 0.000 description 4
239000000872 buffer Substances 0.000 description 4
230000008602 contraction Effects 0.000 description 4
239000006071 cream Substances 0.000 description 4
230000007423 decrease Effects 0.000 description 4
206010012601 diabetes mellitus Diseases 0.000 description 4
238000011156 evaluation Methods 0.000 description 4
239000012894 fetal calf serum Substances 0.000 description 4
125000005842 heteroatom Chemical group 0.000 description 4
230000001969 hypertrophic effect Effects 0.000 description 4
238000010253 intravenous injection Methods 0.000 description 4
210000001117 keloid Anatomy 0.000 description 4
210000000265 leukocyte Anatomy 0.000 description 4
231100000516 lung damage Toxicity 0.000 description 4
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
210000003205 muscle Anatomy 0.000 description 4
239000002674 ointment Substances 0.000 description 4
230000037387 scars Effects 0.000 description 4
210000002966 serum Anatomy 0.000 description 4
238000003786 synthesis reaction Methods 0.000 description 4
238000002560 therapeutic procedure Methods 0.000 description 4
230000017423 tissue regeneration Effects 0.000 description 4
239000003981 vehicle Substances 0.000 description 4
230000004584 weight gain Effects 0.000 description 4
235000019786 weight gain Nutrition 0.000 description 4
238000001262 western blot Methods 0.000 description 4
230000037314 wound repair Effects 0.000 description 4
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
102000004127 Cytokines Human genes 0.000 description 3
108090000695 Cytokines Proteins 0.000 description 3
206010016717 Fistula Diseases 0.000 description 3
206010021143 Hypoxia Diseases 0.000 description 3
206010023421 Kidney fibrosis Diseases 0.000 description 3
208000019693 Lung disease Diseases 0.000 description 3
208000002158 Proliferative Vitreoretinopathy Diseases 0.000 description 3
208000017442 Retinal disease Diseases 0.000 description 3
206010038923 Retinopathy Diseases 0.000 description 3
206010038934 Retinopathy proliferative Diseases 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
108010009583 Transforming Growth Factors Proteins 0.000 description 3
102000009618 Transforming Growth Factors Human genes 0.000 description 3
230000001594 aberrant effect Effects 0.000 description 3
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 3
230000001154 acute effect Effects 0.000 description 3
208000038016 acute inflammation Diseases 0.000 description 3
230000006022 acute inflammation Effects 0.000 description 3
125000003545 alkoxy group Chemical group 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
239000003242 anti bacterial agent Substances 0.000 description 3
229940088710 antibiotic agent Drugs 0.000 description 3
SXTRWVVIEPWAKM-UHFFFAOYSA-N bosentan hydrate Chemical compound O.COC1=CC=CC=C1OC(C(=NC(=N1)C=2N=CC=CN=2)OCCO)=C1NS(=O)(=O)C1=CC=C(C(C)(C)C)C=C1 SXTRWVVIEPWAKM-UHFFFAOYSA-N 0.000 description 3
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
230000001413 cellular effect Effects 0.000 description 3
230000033077 cellular process Effects 0.000 description 3
210000000795 conjunctiva Anatomy 0.000 description 3
230000004069 differentiation Effects 0.000 description 3
230000002500 effect on skin Effects 0.000 description 3
210000002919 epithelial cell Anatomy 0.000 description 3
150000002148 esters Chemical class 0.000 description 3
230000003890 fistula Effects 0.000 description 3
235000013305 food Nutrition 0.000 description 3
230000014509 gene expression Effects 0.000 description 3
244000144993 groups of animals Species 0.000 description 3
125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
238000007912 intraperitoneal administration Methods 0.000 description 3
208000002780 macular degeneration Diseases 0.000 description 3
208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 description 3
210000000440 neutrophil Anatomy 0.000 description 3
229910052760 oxygen Inorganic materials 0.000 description 3
230000037361 pathway Effects 0.000 description 3
210000003200 peritoneal cavity Anatomy 0.000 description 3
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
201000006366 primary open angle glaucoma Diseases 0.000 description 3
230000006785 proliferative vitreoretinopathy Effects 0.000 description 3
239000012453 solvate Substances 0.000 description 3
238000010561 standard procedure Methods 0.000 description 3
230000000638 stimulation Effects 0.000 description 3
238000011477 surgical intervention Methods 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
230000009466 transformation Effects 0.000 description 3
230000004393 visual impairment Effects 0.000 description 3
230000004580 weight loss Effects 0.000 description 3
LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
102000007469 Actins Human genes 0.000 description 2
108010085238 Actins Proteins 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
201000004569 Blindness Diseases 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
208000005590 Choroidal Neovascularization Diseases 0.000 description 2
206010060823 Choroidal neovascularisation Diseases 0.000 description 2
206010012689 Diabetic retinopathy Diseases 0.000 description 2
208000001708 Dupuytren contracture Diseases 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
239000007995 HEPES buffer Substances 0.000 description 2
101000635938 Homo sapiens Transforming growth factor beta-1 proprotein Proteins 0.000 description 2
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
206010020772 Hypertension Diseases 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
229930182816 L-glutamine Natural products 0.000 description 2
239000007987 MES buffer Substances 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
229930192392 Mitomycin Natural products 0.000 description 2
206010028594 Myocardial fibrosis Diseases 0.000 description 2
206010061323 Optic neuropathy Diseases 0.000 description 2
206010034464 Periarthritis Diseases 0.000 description 2
ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical group OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 2
206010035664 Pneumonia Diseases 0.000 description 2
206010037423 Pulmonary oedema Diseases 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
206010050207 Skin fibrosis Diseases 0.000 description 2
201000009594 Systemic Scleroderma Diseases 0.000 description 2
206010042953 Systemic sclerosis Diseases 0.000 description 2
102000040945 Transcription factor Human genes 0.000 description 2
108091023040 Transcription factor Proteins 0.000 description 2
102100030742 Transforming growth factor beta-1 proprotein Human genes 0.000 description 2
102100040247 Tumor necrosis factor Human genes 0.000 description 2
238000012084 abdominal surgery Methods 0.000 description 2
125000004423 acyloxy group Chemical group 0.000 description 2
239000000654 additive Substances 0.000 description 2
230000000996 additive effect Effects 0.000 description 2
125000004414 alkyl thio group Chemical group 0.000 description 2
125000003368 amide group Chemical group 0.000 description 2
125000003277 amino group Chemical group 0.000 description 2
238000000540 analysis of variance Methods 0.000 description 2
238000010171 animal model Methods 0.000 description 2
230000006907 apoptotic process Effects 0.000 description 2
125000006615 aromatic heterocyclic group Chemical group 0.000 description 2
125000003710 aryl alkyl group Chemical group 0.000 description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
239000002585 base Substances 0.000 description 2
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
239000011575 calcium Substances 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
125000001589 carboacyl group Chemical group 0.000 description 2
150000001768 cations Chemical class 0.000 description 2
230000005754 cellular signaling Effects 0.000 description 2
210000003169 central nervous system Anatomy 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
125000001309 chloro group Chemical group Cl* 0.000 description 2
210000004087 cornea Anatomy 0.000 description 2
230000008878 coupling Effects 0.000 description 2
238000010168 coupling process Methods 0.000 description 2
238000005859 coupling reaction Methods 0.000 description 2
125000004093 cyano group Chemical group *C#N 0.000 description 2
125000004122 cyclic group Chemical group 0.000 description 2
125000000392 cycloalkenyl group Chemical group 0.000 description 2
230000006735 deficit Effects 0.000 description 2
150000005690 diesters Chemical class 0.000 description 2
ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
210000001513 elbow Anatomy 0.000 description 2
YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
239000000284 extract Substances 0.000 description 2
230000001605 fetal effect Effects 0.000 description 2
230000000893 fibroproliferative effect Effects 0.000 description 2
230000009795 fibrotic process Effects 0.000 description 2
229960002949 fluorouracil Drugs 0.000 description 2
230000006870 function Effects 0.000 description 2
239000011521 glass Substances 0.000 description 2
125000005843 halogen group Chemical group 0.000 description 2
210000004247 hand Anatomy 0.000 description 2
125000000623 heterocyclic group Chemical group 0.000 description 2
150000004677 hydrates Chemical class 0.000 description 2
150000002430 hydrocarbons Chemical group 0.000 description 2
239000001257 hydrogen Substances 0.000 description 2
125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
230000007954 hypoxia Effects 0.000 description 2
239000007943 implant Substances 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
230000008407 joint function Effects 0.000 description 2
230000003907 kidney function Effects 0.000 description 2
210000003127 knee Anatomy 0.000 description 2
239000007788 liquid Substances 0.000 description 2
238000007726 management method Methods 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
238000005259 measurement Methods 0.000 description 2
208000010125 myocardial infarction Diseases 0.000 description 2
238000011587 new zealand white rabbit Methods 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 2
208000020911 optic nerve disease Diseases 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
230000003204 osmotic effect Effects 0.000 description 2
239000001301 oxygen Substances 0.000 description 2
125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
229910052698 phosphorus Inorganic materials 0.000 description 2
238000002203 pretreatment Methods 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
230000001737 promoting effect Effects 0.000 description 2
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
230000002685 pulmonary effect Effects 0.000 description 2
239000002464 receptor antagonist Substances 0.000 description 2
229940044551 receptor antagonist Drugs 0.000 description 2
230000007115 recruitment Effects 0.000 description 2
230000009467 reduction Effects 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
238000007634 remodeling Methods 0.000 description 2
239000012146 running buffer Substances 0.000 description 2
210000002832 shoulder Anatomy 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
239000011734 sodium Substances 0.000 description 2
DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
238000010254 subcutaneous injection Methods 0.000 description 2
239000007929 subcutaneous injection Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
125000000547 substituted alkyl group Chemical group 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
230000002195 synergetic effect Effects 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
230000008733 trauma Effects 0.000 description 2
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
125000004417 unsaturated alkyl group Chemical group 0.000 description 2
210000003462 vein Anatomy 0.000 description 2
108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
125000000196 1,4-pentadienyl group Chemical group [H]C([*])=C([H])C([H])([H])C([H])=C([H])[H] 0.000 description 1
VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical compound CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
125000006039 1-hexenyl group Chemical group 0.000 description 1
125000006023 1-pentenyl group Chemical group 0.000 description 1
102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 description 1
125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 1
125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 1
125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
125000006041 3-hexenyl group Chemical group 0.000 description 1
MCSXGCZMEPXKIW-UHFFFAOYSA-N 3-hydroxy-4-[(4-methyl-2-nitrophenyl)diazenyl]-N-(3-nitrophenyl)naphthalene-2-carboxamide Chemical compound Cc1ccc(N=Nc2c(O)c(cc3ccccc23)C(=O)Nc2cccc(c2)[N+]([O-])=O)c(c1)[N+]([O-])=O MCSXGCZMEPXKIW-UHFFFAOYSA-N 0.000 description 1
125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
BGNGWHSBYQYVRX-UHFFFAOYSA-N 4-(dimethylamino)benzaldehyde Chemical compound CN(C)C1=CC=C(C=O)C=C1 BGNGWHSBYQYVRX-UHFFFAOYSA-N 0.000 description 1
125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
206010066728 Acute interstitial pneumonitis Diseases 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
108020005544 Antisense RNA Proteins 0.000 description 1
206010003694 Atrophy Diseases 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
238000012935 Averaging Methods 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
102000000905 Cadherin Human genes 0.000 description 1
108050007957 Cadherin Proteins 0.000 description 1
KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
206010007572 Cardiac hypertrophy Diseases 0.000 description 1
208000006029 Cardiomegaly Diseases 0.000 description 1
208000002177 Cataract Diseases 0.000 description 1
102100037182 Cation-independent mannose-6-phosphate receptor Human genes 0.000 description 1
101710145225 Cation-independent mannose-6-phosphate receptor Proteins 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
239000004099 Chlortetracycline Substances 0.000 description 1
208000016216 Choristoma Diseases 0.000 description 1
208000017667 Chronic Disease Diseases 0.000 description 1
201000006306 Cor pulmonale Diseases 0.000 description 1
230000006820 DNA synthesis Effects 0.000 description 1
208000007342 Diabetic Nephropathies Diseases 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
206010013975 Dyspnoeas Diseases 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
238000008157 ELISA kit Methods 0.000 description 1
206010014989 Epidermolysis bullosa Diseases 0.000 description 1
JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
241000027355 Ferocactus setispinus Species 0.000 description 1
102000009123 Fibrin Human genes 0.000 description 1
108010073385 Fibrin Proteins 0.000 description 1
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
230000010337 G2 phase Effects 0.000 description 1
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
229930182566 Gentamicin Natural products 0.000 description 1
241000223783 Glaucoma Species 0.000 description 1
206010018364 Glomerulonephritis Diseases 0.000 description 1
102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
DHCLVCXQIBBOPH-UHFFFAOYSA-N Glycerol 2-phosphate Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 1
229920002683 Glycosaminoglycan Polymers 0.000 description 1
208000031071 Hamman-Rich Syndrome Diseases 0.000 description 1
206010019280 Heart failures Diseases 0.000 description 1
208000013875 Heart injury Diseases 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
206010020880 Hypertrophy Diseases 0.000 description 1
206010061598 Immunodeficiency Diseases 0.000 description 1
208000029462 Immunodeficiency disease Diseases 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
208000032984 Intraoperative Complications Diseases 0.000 description 1
PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
206010023230 Joint stiffness Diseases 0.000 description 1
229930194542 Keto Natural products 0.000 description 1
241000254158 Lampyridae Species 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
208000000185 Localized scleroderma Diseases 0.000 description 1
208000004852 Lung Injury Diseases 0.000 description 1
206010025219 Lymphangioma Diseases 0.000 description 1
102000043136 MAP kinase family Human genes 0.000 description 1
108091054455 MAP kinase family Proteins 0.000 description 1
230000037364 MAPK/ERK pathway Effects 0.000 description 1
208000035719 Maculopathy Diseases 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
SOWBFZRMHSNYGE-UHFFFAOYSA-N Monoamide-Oxalic acid Natural products NC(=O)C(O)=O SOWBFZRMHSNYGE-UHFFFAOYSA-N 0.000 description 1
206010027982 Morphoea Diseases 0.000 description 1
102100025751 Mothers against decapentaplegic homolog 2 Human genes 0.000 description 1
101710143123 Mothers against decapentaplegic homolog 2 Proteins 0.000 description 1
206010062575 Muscle contracture Diseases 0.000 description 1
NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
208000009905 Neurofibromatoses Diseases 0.000 description 1
238000000636 Northern blotting Methods 0.000 description 1
CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
206010029888 Obliterative bronchiolitis Diseases 0.000 description 1
206010030043 Ocular hypertension Diseases 0.000 description 1
206010061137 Ocular toxicity Diseases 0.000 description 1
108091007960 PI3Ks Proteins 0.000 description 1
102000016387 Pancreatic elastase Human genes 0.000 description 1
108010067372 Pancreatic elastase Proteins 0.000 description 1
208000031481 Pathologic Constriction Diseases 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
206010036790 Productive cough Diseases 0.000 description 1
208000004186 Pulmonary Heart Disease Diseases 0.000 description 1
206010037391 Pulmonary granuloma Diseases 0.000 description 1
206010037457 Pulmonary vasculitis Diseases 0.000 description 1
230000006819 RNA synthesis Effects 0.000 description 1
241000242739 Renilla Species 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
238000000692 Student's t-test Methods 0.000 description 1
208000000491 Tendinopathy Diseases 0.000 description 1
206010043255 Tendonitis Diseases 0.000 description 1
206010044245 Toxic optic neuropathy Diseases 0.000 description 1
206010069363 Traumatic lung injury Diseases 0.000 description 1
102000013127 Vimentin Human genes 0.000 description 1
108010065472 Vimentin Proteins 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
206010047571 Visual impairment Diseases 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
201000004073 acute interstitial pneumonia Diseases 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
125000004849 alkoxymethyl group Chemical group 0.000 description 1
125000003282 alkyl amino group Chemical group 0.000 description 1
125000005210 alkyl ammonium group Chemical group 0.000 description 1
150000001350 alkyl halides Chemical class 0.000 description 1
HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
230000008382 alveolar damage Effects 0.000 description 1
210000002821 alveolar epithelial cell Anatomy 0.000 description 1
210000002588 alveolar type II cell Anatomy 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
235000001014 amino acid Nutrition 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
230000003321 amplification Effects 0.000 description 1
206010002022 amyloidosis Diseases 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
210000003423 ankle Anatomy 0.000 description 1
230000008485 antagonism Effects 0.000 description 1
210000002159 anterior chamber Anatomy 0.000 description 1
230000003510 anti-fibrotic effect Effects 0.000 description 1
230000001384 anti-glaucoma Effects 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
230000000340 anti-metabolite Effects 0.000 description 1
229940100197 antimetabolite Drugs 0.000 description 1
239000002256 antimetabolite Substances 0.000 description 1
125000001124 arachidoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
150000001491 aromatic compounds Chemical class 0.000 description 1
125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
125000001769 aryl amino group Chemical group 0.000 description 1
125000005160 aryl oxy alkyl group Chemical group 0.000 description 1
125000004104 aryloxy group Chemical group 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
230000037444 atrophy Effects 0.000 description 1
210000003050 axon Anatomy 0.000 description 1
230000000721 bacterilogical effect Effects 0.000 description 1
125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
102000023732 binding proteins Human genes 0.000 description 1
108091008324 binding proteins Proteins 0.000 description 1
230000007321 biological mechanism Effects 0.000 description 1
230000031018 biological processes and functions Effects 0.000 description 1
239000004305 biphenyl Substances 0.000 description 1
235000010290 biphenyl Nutrition 0.000 description 1
230000037396 body weight Effects 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
125000001246 bromo group Chemical group Br* 0.000 description 1
201000003848 bronchiolitis obliterans Diseases 0.000 description 1
208000023367 bronchiolitis obliterans with obstructive pulmonary disease Diseases 0.000 description 1
125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
244000309466 calf Species 0.000 description 1
239000002775 capsule Substances 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
125000004181 carboxyalkyl group Chemical group 0.000 description 1
125000005026 carboxyaryl group Chemical group 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
238000012754 cardiac puncture Methods 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
230000020411 cell activation Effects 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000022131 cell cycle Effects 0.000 description 1
230000012292 cell migration Effects 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
230000010307 cell transformation Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
230000008859 change Effects 0.000 description 1
150000005829 chemical entities Chemical class 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 description 1
229960004475 chlortetracycline Drugs 0.000 description 1
CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 description 1
235000019365 chlortetracycline Nutrition 0.000 description 1
235000019504 cigarettes Nutrition 0.000 description 1
239000000512 collagen gel Substances 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
210000001608 connective tissue cell Anatomy 0.000 description 1
208000018631 connective tissue disease Diseases 0.000 description 1
208000006111 contracture Diseases 0.000 description 1
208000029078 coronary artery disease Diseases 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
239000003246 corticosteroid Substances 0.000 description 1
201000009805 cryptogenic organizing pneumonia Diseases 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
230000034994 death Effects 0.000 description 1
125000003074 decanoyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 1
230000000593 degrading effect Effects 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
238000000326 densiometry Methods 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
208000033679 diabetic kidney disease Diseases 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
125000004663 dialkyl amino group Chemical group 0.000 description 1
150000008050 dialkyl sulfates Chemical class 0.000 description 1
DENRZWYUOJLTMF-UHFFFAOYSA-N diethyl sulfate Chemical compound CCOS(=O)(=O)OCC DENRZWYUOJLTMF-UHFFFAOYSA-N 0.000 description 1
229940008406 diethyl sulfate Drugs 0.000 description 1
230000010339 dilation Effects 0.000 description 1
125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
229940042400 direct acting antivirals phosphonic acid derivative Drugs 0.000 description 1
208000037765 diseases and disorders Diseases 0.000 description 1
NJDNXYGOVLYJHP-UHFFFAOYSA-L disodium;2-(3-oxido-6-oxoxanthen-9-yl)benzoate Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=CC(=O)C=C2OC2=CC([O-])=CC=C21 NJDNXYGOVLYJHP-UHFFFAOYSA-L 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
238000004980 dosimetry Methods 0.000 description 1
238000002651 drug therapy Methods 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
239000012636 effector Substances 0.000 description 1
230000004406 elevated intraocular pressure Effects 0.000 description 1
208000037888 epithelial cell injury Diseases 0.000 description 1
210000002782 epithelial mesenchymal cell Anatomy 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
210000000416 exudates and transudate Anatomy 0.000 description 1
239000003889 eye drop Substances 0.000 description 1
229940012356 eye drops Drugs 0.000 description 1
210000003195 fascia Anatomy 0.000 description 1
229950003499 fibrin Drugs 0.000 description 1
230000003352 fibrogenic effect Effects 0.000 description 1
230000002615 fibrolytic effect Effects 0.000 description 1
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
125000001153 fluoro group Chemical group F* 0.000 description 1
210000002683 foot Anatomy 0.000 description 1
201000010603 frozen shoulder Diseases 0.000 description 1
125000002541 furyl group Chemical group 0.000 description 1
239000007789 gas Substances 0.000 description 1
238000003304 gavage Methods 0.000 description 1
229960002518 gentamicin Drugs 0.000 description 1
108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
230000037313 granulation tissue formation Effects 0.000 description 1
210000004013 groin Anatomy 0.000 description 1
230000012010 growth Effects 0.000 description 1
125000001188 haloalkyl group Chemical group 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
150000002367 halogens Chemical class 0.000 description 1
125000004970 halomethyl group Chemical group 0.000 description 1
BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
229960003132 halothane Drugs 0.000 description 1
230000036541 health Effects 0.000 description 1
125000000268 heptanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000005241 heteroarylamino group Chemical group 0.000 description 1
125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
210000001624 hip Anatomy 0.000 description 1
230000002962 histologic effect Effects 0.000 description 1
UWYVPFMHMJIBHE-OWOJBTEDSA-N hydroxymaleic acid group Chemical group O/C(/C(=O)O)=C/C(=O)O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
230000003345 hyperglycaemic effect Effects 0.000 description 1
230000001146 hypoxic effect Effects 0.000 description 1
125000002883 imidazolyl group Chemical group 0.000 description 1
238000007654 immersion Methods 0.000 description 1
210000002865 immune cell Anatomy 0.000 description 1
230000007813 immunodeficiency Effects 0.000 description 1
230000002055 immunohistochemical effect Effects 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
125000001041 indolyl group Chemical group 0.000 description 1
230000006698 induction Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
239000011630 iodine Substances 0.000 description 1
125000002346 iodo group Chemical group I* 0.000 description 1
230000002427 irreversible effect Effects 0.000 description 1
229960002725 isoflurane Drugs 0.000 description 1
125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
210000001503 joint Anatomy 0.000 description 1
125000000468 ketone group Chemical group 0.000 description 1
210000003292 kidney cell Anatomy 0.000 description 1
238000002684 laminectomy Methods 0.000 description 1
125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
230000003902 lesion Effects 0.000 description 1
238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
244000144972 livestock Species 0.000 description 1
230000007774 longterm Effects 0.000 description 1
238000003670 luciferase enzyme activity assay Methods 0.000 description 1
238000004020 luminiscence type Methods 0.000 description 1
231100000515 lung injury Toxicity 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
230000000527 lymphocytic effect Effects 0.000 description 1
125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
125000000628 margaroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000003550 marker Substances 0.000 description 1
238000002483 medication Methods 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
208000030159 metabolic disease Diseases 0.000 description 1
HRDXJKGNWSUIBT-UHFFFAOYSA-N methoxybenzene Chemical group [CH2]OC1=CC=CC=C1 HRDXJKGNWSUIBT-UHFFFAOYSA-N 0.000 description 1
JIQNWFBLYKVZFY-UHFFFAOYSA-N methoxycyclohexatriene Chemical compound COC1=C[C]=CC=C1 JIQNWFBLYKVZFY-UHFFFAOYSA-N 0.000 description 1
230000007570 microbleeding Effects 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004001 molecular interaction Effects 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
238000010172 mouse model Methods 0.000 description 1
125000001419 myristoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
230000002988 nephrogenic effect Effects 0.000 description 1
201000004931 neurofibromatosis Diseases 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
201000004071 non-specific interstitial pneumonia Diseases 0.000 description 1
125000001402 nonanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
235000021590 normal diet Nutrition 0.000 description 1
230000037311 normal skin Effects 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
125000002801 octanoyl group Chemical group C(CCCCCCC)(=O)* 0.000 description 1
231100000327 ocular toxicity Toxicity 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
125000002811 oleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
210000001328 optic nerve Anatomy 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
230000002018 overexpression Effects 0.000 description 1
238000012261 overproduction Methods 0.000 description 1
125000002971 oxazolyl group Chemical group 0.000 description 1
125000005704 oxymethylene group Chemical group [H]C([H])([*:2])O[*:1] 0.000 description 1
125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
208000030346 palmar fibromatosis Diseases 0.000 description 1
IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
231100000915 pathological change Toxicity 0.000 description 1
230000036285 pathological change Effects 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
229960001412 pentobarbital Drugs 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
125000005981 pentynyl group Chemical group 0.000 description 1
206010034674 peritonitis Diseases 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical group OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 1
150000003007 phosphonic acid derivatives Chemical class 0.000 description 1
239000004417 polycarbonate Substances 0.000 description 1
229920000515 polycarbonate Polymers 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
229920001296 polysiloxane Polymers 0.000 description 1
238000010837 poor prognosis Methods 0.000 description 1
239000011148 porous material Substances 0.000 description 1
230000002980 postoperative effect Effects 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
159000000001 potassium salts Chemical class 0.000 description 1
239000000843 powder Substances 0.000 description 1
125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
230000002265 prevention Effects 0.000 description 1
238000009117 preventive therapy Methods 0.000 description 1
230000002206 pro-fibrotic effect Effects 0.000 description 1
239000000047 product Substances 0.000 description 1
230000000770 proinflammatory effect Effects 0.000 description 1
230000035752 proliferative phase Effects 0.000 description 1
125000001325 propanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
230000006920 protein precipitation Effects 0.000 description 1
125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
125000003373 pyrazinyl group Chemical group 0.000 description 1
125000003226 pyrazolyl group Chemical group 0.000 description 1
125000002098 pyridazinyl group Chemical group 0.000 description 1
125000004076 pyridyl group Chemical group 0.000 description 1
125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
150000003230 pyrimidines Chemical class 0.000 description 1
125000000168 pyrrolyl group Chemical group 0.000 description 1
238000011002 quantification Methods 0.000 description 1
238000004445 quantitative analysis Methods 0.000 description 1
125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
238000011555 rabbit model Methods 0.000 description 1
239000000700 radioactive tracer Substances 0.000 description 1
238000001959 radiotherapy Methods 0.000 description 1
238000003753 real-time PCR Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
210000003994 retinal ganglion cell Anatomy 0.000 description 1
238000005070 sampling Methods 0.000 description 1
201000000306 sarcoidosis Diseases 0.000 description 1
229930195734 saturated hydrocarbon Natural products 0.000 description 1
210000003786 sclera Anatomy 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
229910052711 selenium Inorganic materials 0.000 description 1
238000012764 semi-quantitative analysis Methods 0.000 description 1
239000012679 serum free medium Substances 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
231100000075 skin burn Toxicity 0.000 description 1
208000017520 skin disease Diseases 0.000 description 1
230000000391 smoking effect Effects 0.000 description 1
210000002460 smooth muscle Anatomy 0.000 description 1
238000002791 soaking Methods 0.000 description 1
239000007974 sodium acetate buffer Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
229940054269 sodium pyruvate Drugs 0.000 description 1
238000007614 solvation Methods 0.000 description 1
238000010186 staining Methods 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
230000001629 suppression Effects 0.000 description 1
239000003826 tablet Substances 0.000 description 1
201000004415 tendinitis Diseases 0.000 description 1
125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
125000000335 thiazolyl group Chemical group 0.000 description 1
230000008719 thickening Effects 0.000 description 1
125000001544 thienyl group Chemical group 0.000 description 1
125000003396 thiol group Chemical class [H]S* 0.000 description 1
150000003573 thiols Chemical class 0.000 description 1
230000009772 tissue formation Effects 0.000 description 1
230000007838 tissue remodeling Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
210000003437 trachea Anatomy 0.000 description 1
238000001890 transfection Methods 0.000 description 1
YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
238000011870 unpaired t-test Methods 0.000 description 1
125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
230000002792 vascular Effects 0.000 description 1
210000005048 vimentin Anatomy 0.000 description 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
208000029257 vision disease Diseases 0.000 description 1
230000000007 visual effect Effects 0.000 description 1
238000003260 vortexing Methods 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
238000005303 weighing Methods 0.000 description 1
230000010388 wound contraction Effects 0.000 description 1
210000000707 wrist Anatomy 0.000 description 1
239000008096 xylene Substances 0.000 description 1